Sharon Adkins, MSN, RN
Tennessee Nurses Association
545 Mainstream Drive, Suite 405
Prior to assuming leadership for the state's professional nursing organization in 2006, Adkins held various leadership positions over two decades at Vanderbilt. She holds an undergraduate degree in nursing from the University of Minnesota, a master's in nursing administration from VUSN, and is a 1997 graduate of the Parish Nurse Preparation Institute at the Marquette University College of Nursing. At Vanderbilt, she developed and directed the Center for Parish Nursing and Health Ministries and is a past president of the National Health Ministries Association. Adkins is a past Nashville Medical News "Women to Watch" honoree.
A Polygenic Risk Score -- a genetic assessment that doctors have hoped could predict coronary heart disease (CHD) in patients -- has been found not to be a useful predictive biomarker for disease risk, according to a Vanderbilt study published in the Journal of the American Medical Association.
Most Tennessee infants exposed to hepatitis C at birth are not later tested to see if they acquired the virus, according to a study by researchers at Monroe Carell Jr. Children's Hospital at Vanderbilt and the Vanderbilt Center for Child Health Policy.
With the Tennessee General Assembly back in full swing, the state's major healthcare associations outline 2020 priorities.
From transplants to trials, Nashville hospitals are leading the way in cardiac care.
Technology has changed every aspect of our lives. In fact, I had a healthy laugh a few weeks ago when I showed my children an old rotary phone and, get this, they did not know what it was.
In late January, a group of more than 25 organizations from across Tennessee announced their support for legislation that seeks to prevent the next generation of nicotine addicts in the state.
TriStar Summit cardiologist Kristen Kerr is passionate about education, improving outcomes in women's heart health.
Following successful preclinical trials and FDA funding, Cumberland Pharmaceuticals is preparing to launch a new Phase II trial of ifetroban to treat cardiomyopathy in Duchenne Muscular Dystrophy patients.
Endocrine Society Chief Professional & Clinical Affairs Officer Robert Lash, MD, discusses the field, annual meeting, road shows and more.